Entrada Therapeutics, Inc. announced the appointment of Dr. Bernhardt “Bernie” Zeiher to its Board of Directors, effective immediately. Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma. Dr. Zeiher started his career at Astellas in 2010 as Vice President and Therapeutic Area Leader for Inflammation, Immunology and Infectious Diseases.

He was promoted to Senior Vice President and Therapeutic Area Head for Immunology, Infectious Diseases and Transplant in 2012. Dr. Zeiher was later named Executive Vice President and Therapeutic Area Head when his responsibilities expanded to include the company's development operations and clinical pharmacology departments. He was promoted to President of Development in 2015, and most recently to Chief Medical Officer in 2018.

Prior to joining Astellas, Dr. Zeiher served as Vice President of the Inflammation and Immunology Therapeutic Area at Pfizer and Medical Director for Inflammation and Immunology at Eli Lilly. Throughout his career, he has participated in the development and approval of 15 products across multiple therapeutic areas. Dr. Zeiher earned his Doctor of Medicine at the Case Western Reserve University School of Medicine and completed an internal medicine residency at University Hospitals of Cleveland as well as a fellowship in Pulmonary and Critical Care Medicine at University of Iowa Hospitals and Clinics.

He is also a Fellow in the American College of Physicians and the American College of Chest Physicians.